Santhera Secures Swiss Approval for AGAMREE as Nxera Expands Asia-Pacific Access for Duchenne Muscular Dystrophy Treatment
Key Insights
Santhera Pharmaceuticals received Swissmedic (search) approval for AGAMREE (vamorolone) to treat Duchenne muscular dystrophy (search) in patients four years and older, marking the company's seventh global marketing approval.
Nxera Pharma (search) secured exclusive licensing rights for vamorolone in Japan, South Korea, Australia, and New Zealand through a $40 million upfront deal with potential milestone payments up to $165 million.
The novel dissociative steroid demonstrated superior safety compared to traditional corticosteroids (search), with five-year data showing reduced vertebral fractures, lower cataract incidence, and maintained normal growth rates.
Santhera Pharmaceuticals has achieved a significant regulatory milestone with Swiss approval of AGAMREE (vamorolone) for treating Duchenne muscular dystrophy (search) (DMD (search)), while simultaneously expanding global access through a strategic licensing partnership with Nxera Pharma (search) for key Asia-Pacific markets.
The Swiss Agency for Therapeutic Products (Swissmedic (search)) approved AGAMREE for DMD (search) treatment in patients four years of age and older on January 15, 2026. This marks Santhera's seventh global marketing approval for the novel dissociative steroid, which is already approved in the US, European Union, UK, China, Hong Kong, and Canada.
"As a proudly Switzerland-based business, securing Swissmedic (search) approval represents an important achievement, and marks our seventh global marketing approval," said Dario Eklund, Chief Executive Officer of Santhera. "We expect to launch AGAMREE in Switzerland later in 2026, in order to ensure timely access to this important therapy for DMD (search) patients in the country."
Expanding Asia-Pacific Market Access
In a parallel development, Nxera Pharma (search) entered an exclusive licensing agreement with Santhera for vamorolone development, manufacturing, and commercialization rights in Japan, South Korea, Australia, and New Zealand. The transaction includes a $40 million upfront payment comprising $30 million in cash and $10 million as a strategic equity investment.
Santhera remains eligible for additional sales and regulatory milestone payments up to $165 million, plus tiered royalties starting in the low teens on net sales in the licensed territories. This partnership leverages Nxera's established commercial infrastructure and regulatory expertise across the Asia-Pacific region.
"Vamorolone's differentiated safety and efficacy profile has the potential to fundamentally change the standard of care by enabling early use, full dosing, and long-term treatment, addressing critical limitations of existing steroid therapies currently used in the region," commented Christopher Cargill, President and Chief Executive Officer of Nxera.
Superior Safety Profile Demonstrated
AGAMREE represents a significant advancement over traditional corticosteroids (search), the current standard of care for DMD (search). The drug binds to the same receptor as glucocorticoids (search) but modifies downstream activity while avoiding substrate interaction with 11-β-hydroxysteroid dehydrogenase (search) enzymes responsible for local drug amplification and corticosteroid-associated toxicity.
In the pivotal Phase 2b VISION-DMD (search) study, AGAMREE met its primary endpoint of Time to Stand (TTSTAND) velocity versus placebo with statistical significance (p=0.002) at 24 weeks of treatment. The most commonly reported side effects included cushingoid features, vomiting, weight increase, and irritability, generally of mild to moderate severity.
Long-term safety data from the five-year GUARDIAN study highlighted substantially improved outcomes compared to conventional corticosteroids (search). The data showed reduced vertebral fractures, lower incidence of cataracts, and maintenance of normal growth rates. Unlike traditional corticosteroids, AGAMREE demonstrated no growth restriction and no negative effects on bone metabolism, as evidenced by normal bone formation and resorption serum markers.
Addressing Significant Unmet Need
DMD (search) is a rare inherited X-chromosome-linked disease affecting almost exclusively males, characterized by progressive muscle degeneration and weakness due to inflammation-induced fibrosis. The condition reduces life expectancy to before the fourth decade due to respiratory and cardiac failure, with major disease milestones including loss of ambulation, loss of self-feeding, need for assisted ventilation, and development of cardiomyopathy.
Switzerland has over 200 people affected by DMD (search) with limited treatment options currently available. Santhera has been granted a 15-year exclusivity period under Swiss orphan drug status and anticipates commercial launch in the second half of 2026 following completion of national pricing and reimbursement procedures.
Commercial Strategy and Market Positioning
The Swiss approval was based on data from the pivotal VISION-DMD (search) study and assessment results from the European Medicines Agency. Santhera retains exclusive distribution rights for AGAMREE in Switzerland while continuing to expand global access through strategic partnerships.
The company has previously out-licensed rights to Catalyst Pharmaceuticals for North America and to Sperogenix Therapeutics (search) for China and certain Southeast Asian countries. The new Nxera partnership extends this strategy to key Asia-Pacific markets, positioning AGAMREE as a potential replacement for existing corticosteroid therapies across multiple regions.
AGAMREE's positioning as a dissociative anti-inflammatory drug addresses a critical gap in DMD (search) treatment by potentially separating therapeutic efficacy from steroid-associated safety concerns, offering clinicians and patients a more favorable risk-benefit profile for long-term management of this devastating neuromuscular condition.